bluuebunny/crossref_metadata_2025_split huggingface dataset:
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation
Authors: Abel Gregory A. , Kim Haesook T. , Zackon Ira , Alyea Edwin T. , Bailey Alexandra S. , Winters John P. , Meehan Kenneth R. , Reagan John L. , Walsh Jeanna H. , Walsh Thomas P. , Ivanov Alexandra , Faggen Meredith A. , Sinclair Sarah , Joyce Amy C. , Close Sara D. , Emmert Amy , Koreth Jon , Antin Joseph H. , Cutler Corey S. , Ho Vincent T. , Soiffer Robert J. 
Published: January 2025

ImportanceAlthough sharing care with local oncologists after allogeneic hematopoietic cell transplantation (HCT) has been proposed for patients living far from HCT centers, it is not known whether a shared strategy is safe or improves patient quality of life (QOL).ObjectiveTo determine the efficacy and safety of sharing follow-up care after HCT between the HCT specialty center and local oncologists.Design, Setting, and ParticipantsThis was a multicenter collaborative randomized clinical trial of patients undergoing HCT at Dana-Farber Cancer Institute (DFCI)—a high volume HCT center in Boston (Massachusetts)—and 8 local oncology practices. Eligible patients were enrolled from December 2017 to December 2021 and were randomized 1:1 to shared vs usual care after neutrophil engraftment, stratified by local sites in Massachusetts, Rhode Island, New Hampshire, New York, and Maine. Data analyses were performed in January 2024.InterventionShared care involved alternating post-HCT visits at DFCI and local oncology practices through day 100; for usual care, all post-HCT visits occurred only at DFCI.Main Outcomes and MeasuresCoprimary outcomes were nonrelapse mortality (NRM) at day 100, and QOL measured by the FACT-BMT (Functional Assessment of Cancer Therapy–Bone Marrow Transplantation) instrument and the QLQ-C30 (European Organization for Research and Treatment of Cancer’s Quality of Life Questionnaire) at day 180. Prespecified secondary outcomes included day 100 QOL and 1-year overall survival.ResultsA total of 302 participants (median [range] age, 63 [20-79] years; 117 [38.7%] females; 185 [61.3%] males) were included in the analysis; 152 were randomized to shared care and 150 to usual care. Day 100 NRM was noninferior for shared vs usual care (2.6% [95% CI, 0.7% to 6.6%] vs 2.7% [95% CI, 0.7% to 6.7%]; P = .98). There were no differences at day 180 for the FACT-BMT total score (mean difference, 3.8; 95% CI, −2.1 to 9.6; P = .20) or QLQ-C30 global score (1.9; 95% CI, −4.9 to 8.8; P = .58). At day 100, the FACT-BMT total score was better for shared care (mean difference, 6.6; 95% CI, 1.0 to 12.1; P = .02) as was the QLQ-C30 global score (8.8; 95% CI, 1.8 to 15.7; P = .02).Conclusions and RelevanceThis randomized clinical trial found that shared care resulted in noninferior NRM at day 100 but similar QOL at day 180, with improved QOL at day 100. These data suggest that shared care is safe, improves QOL early on, and has the potential to become a routine model for post-HCT care.Trial RegistrationClinicalTrials.gov Identifier: NCT03244826
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies
Authors: Arora Kanika , Suehnholz Sarah P. , Zhang Hongxin , Ostrovnaya Irina , Kundra Ritika , Nandakumar Subhiksha , Nissan Moriah H. , Brannon A. Rose , Bandlamudi Chaitanya , Ladanyi Marc , Drilon Alexander , Brown Carol L. , Solit David B. , Schultz Nikolaus , Berger Michael F. , Chakravarty Debyani 
Published: January 2025

ImportanceAlthough differences in the prevalence of key cancer-specific somatic mutations as a function of genetic ancestry among patients with cancer has been well-established, few studies have addressed the practical clinical implications of these differences for the growing number of biomarker-driven treatments.ObjectiveTo determine if the approval of precision oncology therapies has benefited patients with cancer from various ancestral backgrounds equally over time.Design, Setting, and ParticipantsA retrospective analysis of samples from patients with solid cancers who underwent clinical sequencing using the integrated mutation profiling of actionable cancer targets (MSK-IMPACT) assay between January 2014 and December 2022 was carried out. The annual fraction of patients per ancestral group with at least 1 level 1 biomarker was calculated for FDA drug approvals from January 1998 to December 2023. Analysis began in January 2024.Main Outcomes and MeasuresFor each patient, genetic ancestry was quantitatively inferred, and patients were grouped based on predominant reference ancestry. OncoKB was used to identify all Food and Drug Administration (FDA)–recognized somatic biomarkers associated with FDA-approved therapies (level 1 biomarkers) in each tumor sample.ResultsOverall, the study included 59 433 patients. The approval of the EGFR-tyrosine kinase inhibitor erlotinib for patients with EGFR-mutant lung cancers in 2013 disproportionately benefited patients of East Asian and South Asian ancestries, leading to higher patient fractions with level 1 biomarkers in these ancestral groups compared with other populations. Although the increase in precision oncology drug approvals from 2019 to 2020 had a notable positive impact on clinical actionability for patients of European ancestry, patients of African ancestry had the lowest fraction of level 1 biomarkers compared with other groups from 2019 onward.Conclusion and RelevanceThis study systematically assessed and compared temporal changes in genomic biomarker-based eligibility for precision oncology therapies as a function of inferred genetic ancestry derived from DNA sequencing data. Despite the accelerated rate of FDA approvals for precision oncology therapies over the past decade, measurable differences in biomarker-based drug eligibility among patient ancestral groups exist. These differences may exacerbate the systemic disparities in clinical outcomes in patients of African ancestry due to existing deficiencies in their access to cancer care.
Interaction between riluzole treatment and dietary glycemic index in the disease progression of amyotrophic lateral sclerosis
Authors: Lee Ikjae , Mitsumoto Hiroshi , Lee Seonjoo , Kasarskis Edward , Rosenbaum Michael , Factor‐Litvak Pam , Nieves Jeri W. 
Published: January 2025

AbstractObjectiveWe examined whether riluzole treatment modifies the associations between the dietary glycemic index (GI) and load (GL) and disease progression in amyotrophic lateral sclerosis (ALS).MethodsSporadic ALS patients in the Multicenter Cohort Study of Oxidative Stress who completed a baseline food frequency questionnaire were included (n = 304). Interactions between baseline riluzole treatment and GI/GL on functional decline and tracheostomy‐free survival were examined using linear regression and Cox proportional hazard models adjusted for covariates. Age, sex, disease duration, diagnostic certainty, body mass index, bulbar onset, revised ALS functional rating scale (ALSFRS‐r) total score, and forced vital capacity, from baseline were included as covariates.ResultsBaseline higher GI and GL were associated with less decline of ALSFRS‐r total score at 3‐month follow‐up in the riluzole treatment group (RTG) but not in the no‐riluzole group (NRG). When quartile groups were used, GI second [β = −1.9, 95% CI (−4.1, −0.2), p = 0.07], third [β = −3.0, 95% CI (−5.1, −0.8), p < 0.01] and fourth [β = −2.2, 95% CI (−4.3, −0.01), p < 0.05] quartile groups were associated with less ALSFRS‐r decline at 3‐months compared to the first quartile group (GI < 47.2) among the RTG. Similarly, GL fourth quartile group (GL > 109.5) was associated with less ALSFRS‐r decline at 3 months compared to the first quartile group [β = −2.6, 95% CI (−4.7, −0.5), p < 0.05] among the RTG. In NRG, no statistically significant differences in ALSFRS‐r decline were found among GI/GL quartile groups.InterpretationHigh dietary GI and GL are associated with a slower functional decline only among ALS patients taking riluzole.
Asynchronous Resilient Filtering for Singular Perturbation Stochastic Semi‐Markov CPSs Against Stochastic Cyber Attacks
Authors: Wang Yanqian , Yang Zhibo , Zhuang Guangming , Lv Chengxing 
Published: January 2025

ABSTRACTThe article investigates the problem of asynchronous resilient filter design for cyber‐physical systems (CPSs) under multiple cyber‐attacks, which are characterized by singular perturbation and stochastic semi‐Markov jump systems (SPSS‐MJSs) with a dynamic‐memory event‐triggered (DMET) scheme. Firstly, we consider the vulnerability of communication network and establish a unified cyber‐attack framework to address the occurrences of deception attacks and denial‐of‐service (DoS) attacks, simultaneously. Then, we introduce the function of the memorizer and propose the DMET scheme, which can effectively save network resources in bandwidth‐limited environments. Since the mode information of the resilient filter is often unavailable, we employ a hidden Markov model (HMM) to describe the asynchronous relationship between the modes of the original system and the constructed filter. Furthermore, we judiciously select a stochastic Lyapunov functional concerning the internal dynamic variable, which results in the stochastically admissible criterion for filtering error systems under complex cyber‐attacks. The co‐design approach is adopted to obtain the gains of the asynchronous resilient filter and the DMET scheme. Finally, a continuous stirred‐tank reactor (CSTR) system is offered to validate the effectiveness of the developed method.
Multifunctional Hydrogel with Photothermal ROS Scavenging and Antibacterial Activity Accelerates Diabetic Wound Healing
Authors: Xue Yijia , Yang Fan , He Yunjiao , Wang Feilong , Xia Dandan , Liu Yunsong 
Published: January 2025

AbstractPoor diabetic wound healing poses a critical threat to human health. Excessive oxidative stress and increased susceptibility to bacterial infection are key issues that impede diabetic wound healing. Cerium oxide nanoparticles (CeO2 NPs) have attracted increasing attention because of their unique antioxidant and antimicrobial properties. Here, this work designs a near‐infrared (NIR) light‐responsive gelatin methacryloyl (GelMA)/CeO2/polydopamine (PDA) hydrogel with antibacterial and antioxidant effects. The hydrogel exhibits a stable, efficient, and controllable photothermal conversion capacity under NIR stimulation. The hydrogel can be used to construct a local microenvironment conducive to chronic diabetic wound healing. Significant antibacterial effects of the NIR‐responsive GelMA/CeO2/PDA hydrogel on both Escherichia coli (E.coli) and methicillin‐resistant Staphylococcus aureus (MRSA) are demonstrated by counting colony‐forming units (CFUs) and in bacterial live/dead staining experiments. The strong antioxidant activity of hydrogels is demonstrated by measuring the level of reactive oxygen species (ROS). The effect of the NIR‐responsive GelMA/CeO2/PDA hydrogel in terms of promoting diabetic wound healing is validated in full‐thickness cutaneous wounds of diabetic rat models. Additionally, this work describes the mechanism by which the NIR‐responsive GelMA/CeO2/PDA hydrogel promotes diabetic wound healing; the hydrogel inhibits the interleukin (IL)‐17 signaling pathway. This NIR‐responsive, multifunctional hydrogel dressing provides a targeted approach to diabetic wound healing.
Ag‐Cu Nanoarchitecture for Enhanced LSPR Absorption: the Role of Surface Roughness and near‐field Interactions
Authors: Kumar Sanjay , Curda Pavel , Maskova Hana , Doudová Lenka , Pleskunov Pavel , Kuzminova Anna , Hejduk Libor , Sterba Jan , Kylián Ondřej , Rego Ryan O. M. , Stranak Vitezslav 
Published: January 2025

AbstractThe plasmonic properties and biosensing performance of a nanocomposite with incorporated Cu and Ag nanoparticles (NPs) are studied experimentally. The concept's viability is verified by detecting specific anti‐decorin‐binding protein A (DbpA) from Borrelia afzelii antibodies, typically produced by a living organism in response to Lyme disease infection, carried out in real‐life negative and positive blood sera. It is shown that the addition of Cu NPs on top of silver NPs regularly boosts the plasmonic absorption caused by optical and electrical changes in the vicinity of the surface compared to silver NPs only. The Finite‐difference time‐domain (FDTD) simulations of near‐field interaction in different environments propose suitable Cu–Ag coupling modes responsible for the modulation of the localized Surface Plasmon Resonance (LSPR) bands. Furthermore, the increased surface roughness, resulting from the architecture of combined nanoparticles of different metals, significantly enlarges the effective surface area for sensing applications, which consequentially leads to better species immobilization. The observed distinguishable differences between the negative and positive sera of LSPR response, and the high sensitivity and selectivity together with high stability of the nanocomposite (suppressed aging) opens a door for concepts of rapid, low‐cost, sensitive LPSR‐based biodetection platforms.
Microneedles with Interdigitated Electrodes for In Situ Impedimetric VEGF Sensing
Authors: Das Ritu , Istif Emin , Cebecioglu Rumeysa , Ali Mohsin , Atik Yasin , Dağ Çağdaş , Celikbas Eda , Demirci Gozde , Acar FundaYagcı , Hasanreisoğlu Murat , Beker Levent 
Published: January 2025

AbstractContinuous monitoring of protein biomarkers in interstitial fluid (ISF) is essential for improving patient care and outcomes. This study presents a novel electrochemical impedance spectroscopy (EIS) sensor utilizing microneedles (MNs) patterned with interdigitated electrodes for the detection of vascular endothelial growth factor (VEGF). The MNs, are fabricated from flexible polylactide (PLA) using a simple molding technique, followed by metal deposition with an interdigitated pattern to serve as a platform for the EIS sensor. After functionalization with anti‐VEGF antibodies, impedance measurements are conducted to detect VEGF levels, demonstrating a significant change in impedance in response to varying concentrations of the target biomarker. The MNs can easily penetrate rat skin by hand, puncturing without mechanical breakage. This innovative approach enhances the sensitivity and specificity of biomarker detection and paves the way for continuous monitoring applications in diagnostics and preventative medicine.
Metabolic‐Immune Suppression Mediated by the SIRT1‐CX3CL1 Axis Induces Functional Enhancement of Regulatory T Cells in Colorectal Carcinoma
Authors: Zi Ruiyang , Zhao Xiang , Liu Limei , Wang Yijie , Zhang Rui , Bian Zhiheng , Jiang Haoran , Liu Taorui , Sun Yixin , Peng Han , Wang Xuesong , Lu Fanghao , Zhang Chao , Zhang Fan , Qin Qing , Liang Houjie , Li Jianjun , Wei Zhihao , Dong Yan 
Published: January 2025

AbstractMetabolic reprogramming of tumor cells dynamically reshapes the distribution of nutrients and signals in the tumor microenvironment (TME), affecting intercellular interactions and resulting in metabolic immune suppression. Increased glucose uptake and metabolism are characteristic of many tumors. Meanwhile, the progression of colorectal carcinoma (CRC) relies on lipid metabolism. Therefore, investigating the role of glucolipid metabolic reprogramming on tumor immunity contributes to identifying new targets for immune suppression intervention in CRC. Our previous work demonstrated that SIRT1 is the hub gene involved in glucolipid metabolic conversion in CRC. Here, it is found that upregulated SIRT1 in CRC cells increases Treg functionality by promoting the secretion of CX3CL1. The CX3CL1‐CX3CR1 signaling activated transcription factors SATB1 and BTG2, promoting the differentiation of TCF7+ Treg cells into functionally enhanced TNFRSF9+ Treg cells. Multiplex immunofluorescence (mIHC) analysis of a CRC tissue microarray confirmed the promoting effect of CX3CL1 on Treg infiltration. Additionally, the therapeutic efficacy of CX3CR1 inhibitor monotherapy and combination therapy is validated with the PD‐1 antibody in the humanized subcutaneous CRC mouse model. This study elucidates a potential mechanism that metabolic reprogramming of cancer cells collaborates with subsequent immunosuppression to promote CRC progression.
A Dual‐Targeting Biomimetic Nanoplatform Integrates SDT/CDT/Gas Therapy to Boost Synergistic Ferroptosis for Orthotopic Hepatocellular Carcinoma Therapy
Authors: Meng Wen , Chen Ting , Li Xueping , Li Yi , Zhang Lu , Xu Yigang , Song Tianqiang , Qi Ji , Xiong Qingqing , Li Wen 
Published: January 2025

AbstractThe development of efficient therapeutic strategies to promote ferroptotic cell death offers significant potential for hepatocellular carcinoma (HCC) treatment. Herein, this study presents an HCC‐targeted nanoplatform that integrates bimetallic FeMoO4 nanoparticles with CO‐releasing molecules, and further camouflaged with SP94 peptide‐modified macrophage membrane for enhanced ferroptosis‐driven multi‐modal therapy of HCC. Leveraging the multi‐enzyme activities of the multivalent metallic elements, the nanoplatform not only decomposes H2O2 to generate oxygen and alleviate tumor hypoxia but also depletes glutathione to inactivate glutathione peroxides 4, which amplify sonodynamic therapy and ferroptotic tumor death under ultrasound (US) irradiation. Meanwhile, the nanoplatform catalyzes the Fenton reaction to produce hydroxyl radicals for chemodynamic therapy. Elevated intracellular reactive oxygen species trigger the cascade release of CO, leading to lethal lipid peroxidation and further enhancing ferroptosis‐mediated tumor therapy. This nanoplatform demonstrates robust anti‐tumor efficacy under US irradiation with favorable biosafety in both subcutaneous and orthotopic HCC models, representing a promising therapeutic approach for HCC. Additionally, the findings offer new insights into tumor microenvironment modulation to optimize US‐triggered multi‐modal cancer therapy.
Breaking the Trade‐Off Between Electrical Conductivity and Mechanical Strength in Bulk Graphite Using Metal–Organic Framework‐Derived Precursors
Authors: Zhang Yuqing , Wang Junzhuo , Zhang Yinghan , Zheng Qi , Wang Lianjun , Jiang Wan 
Published: January 2025

AbstractHigh‐performance bulk graphite (HPBG) that simultaneously integrates superior electrical conductivity and excellent strength is in high demand, yet it remains critical and challenging. Herein a novel approach is introduced utilizing MOF‐derived nanoporous metal/carbon composites as precursors to circumvent this traditional trade‐off. The resulting bulk graphite, composed of densely packed multilayered graphene sheets functionalized with diverse cobalt forms (nanoparticles, single atoms, and clusters), exhibits unprecedented electrical conductivity in all directions (in‐plane: 7311 S cm⁻¹, out‐of‐plane: 5541 S cm⁻¹) and excellent mechanical strength (flexural: 101.17±5.73 MPa, compressive: 151.56±2.53 MPa). Co nanoparticles act as autocatalysts and binders, promoting strong interlayer adhesion among highly graphitized graphene layers via spark plasma sintering. The strong nano‐interfaces between graphite and Co‐create critical bridges between graphene nanosheets, facilitating highly efficient electron migration and enhanced strength and stiffness of the assembled bulk nanocomposites. Leveraging these exceptional properties, practical demonstrations highlight the immense potential of the robust material for applications demanding superior electromagnetic interference shielding and efficient heating. An innovative approach, which effectively decouples electrical conductivity from mechanical properties, paves the way for the creation of HPBGs tailored for diverse application sectors.
Effectiveness of advanced dressings in preventing surgical site infections compared to that of standard dressings in gastrointestinal surgery: A systematic review and meta‐analysis for guideline revision by the Japanese Society for Surgical Infection
Authors: Kouzu Keita , Tsujimoto Hironori , Shinji Seiichi , Shinkawa Hiroji , Tamura Koji , Sato Yukio , Munakata Koji , Fukuda Yasunari , Koike Daisuke , Miyake Hiromu , Hosoda Yohei , Uchino Motoi , Ohge Hiroki , Shimizu Junzo , Haji Seiji , Mohri Yasuhiko , Yamashita Chizuru , Kitagawa Yuichi , Kobayashi Motomu , Hanai Yuki , Nobuhara Hiroshi , Yoshida Masahiro , Mizuguchi Toru , Mayumi Toshihiko , Kitagawa Yuko 
Published: January 2025

AbstractIntroductionThis is a systematic review and meta‐analysis of the efficacy of wound coverage using advanced dressings specifically for the prevention of surgical site infections (SSI) in gastrointestinal surgery, as part of the update of the SSI prevention guidelines of the Japan Society for Surgical Infection (JSSI).MethodsAfter searching CENTRAL, PubMed, and ICHUSHI‐Web in July 2024, we included randomized controlled trials (RCTs) comparing advanced dressings and standard dressings for surgical wounds in gastrointestinal surgery (PROSPERO No. CRD42024569084). Three authors independently screened the RCTs. We assessed the risk of bias and certainty of the body of evidence for the extracted data. The primary outcome was superficial SSI, and the secondary outcomes were length of postoperative hospital stay, costs, and allergy. This study was partially supported by the JSSI.ResultsA total of seven RCTs and 927 patients were included. The use of advanced dressings significantly lowered the risk of SSI compared to that associated with standard dressings (risk ratio: 0.54, 95% confidence intervals: 0.34–0.88). The certainty of the evidence was rated as moderate. According to the subgroup analysis, advanced dressings reduced the risk of SSI in colorectal surgery. Advanced dressings did not reduce the length of postoperative hospital stay or costs compared to that of standard dressings. Allergies were reported in only one patient using silver‐impregnated dressings.ConclusionThe use of advanced dressings for primary wounds in gastrointestinal surgery was associated with a significantly lower risk of SSI than that associated with standard dressings.
Revolutionizing Bone Regeneration: Vascularized Bone Tissue Engineering with Advanced 3D Printing Technology
Authors: Fan Jiaxuan , Ding Zichuan , Cai Yongrui , Lai Yahao , Huang Chao , Jiang Boyi , Zhou Zongke , Luo Zeyu 
Published: January 2025

ABSTRACTThe repair and functional reconstruction of bone defects resulting from trauma, surgical resection, degenerative diseases, and congenital malformations are major clinical challenges. Bone tissue engineering has significant advantages in the treatment of severe bone defects. Vascularized bone repair scaffolds are gradually attracting attention and development because of their excellent biomimetic properties and efficient repair efficiency. Three‐dimensional (3D) printing technology, which can be used to fabricate structures at different scales using a wide range of materials, has been used in the production of vascularized bone repair scaffolds. This review discusses the research progress in 3D printing for vascularized bone repair scaffolds. Angiogenesis‐osteogenesis coupling in the bone regeneration process is first introduced, followed by a summary of the 3D printing technologies, printing inks, and bioactive factors used to fabricate vascularized bone repair scaffolds. Notably, this review focuses on structural design strategies for vascularized bone repair scaffolds. Finally, the application of vascularized bone repair scaffolds in medicine, as well as challenges and outlooks for future development, are described.